Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Y2ZN
|
||||
Former ID |
DNCL002128
|
||||
Drug Name |
Oral azacitidine
|
||||
Company |
Celgene
|
||||
Target and Pathway | |||||
Target(s) | DNMT1 | Target Info | Inhibitor | [528903] | |
Pathway Interaction Database | Regulation of retinoblastoma protein | ||||
PathWhiz Pathway | Methionine Metabolism | ||||
References | |||||
Ref 524889 | ClinicalTrials.gov (NCT02223052) CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies. U.S. National Institutes of Health. | ||||
Ref 531480 | Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20;29(18):2521-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.